Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peripheral Artery Treatment Clear all
Recruiting No phase listed Observational

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

NCT05145478
View directory record Official record
Conditions
Femoral Arterial Calcification, Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
Interventions
Shockwave Intravascular Lithotripsy (IVL)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 1 Interventional

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

NCT00951210
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
40 Years to 81 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Birmingham, Alabama • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 1, 2026, 9:18 PM EDT
Withdrawn Phase 1 Interventional

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

NCT02953496
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
vonapanitase
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 4 Interventional Results available

GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study

NCT00228384
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
GORE VIABAHN Endoprosthesis, Bare Nitinol Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 1, 2026, 9:18 PM EDT
Recruiting Not applicable Interventional

The Effects of Diet and Exercise Interventions in Peripheral Artery Disease

NCT03845036
View directory record Official record
Conditions
Claudication, Peripheral Artery Disease
Interventions
DASH Diet plus Home-Based Exercise, Home-Based Exercise
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 1, 2026, 9:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Augmentation of Limb Perfusion With Contrast Ultrasound

NCT03195556
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ultrasound
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
19 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Not applicable Interventional Results available

The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions

NCT00814970
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Complete SE Vascular Stent System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Fremont, California • Gainesville, Florida • Ocala, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 1, 2026, 9:18 PM EDT
Recruiting Phase 2Phase 3 Interventional

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
CSL300, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
166
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.

NCT00798005
View directory record Official record
Conditions
Severe Peripheral Artery Occlusive Disease
Interventions
XRP0038 (NV1FGF)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 1, 2026, 9:18 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Onsite Tobacco Cessation Treatment for Patients With PAD

NCT05469698
View directory record Official record
Conditions
Tobacco Cessation, Peripheral Artery Disease
Interventions
Tobacco Treatment Research Program Standard Care
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 1, 2026, 9:18 PM EDT
Active, not recruiting Not applicable Interventional

A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)

NCT03477604
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
MicroStent and Standard PTA, Standard PTA
Device
Lead sponsor
Micro Medical Solution, Inc.
Industry
Eligibility
21 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Mesa, Arizona • St. Helena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 1, 2026, 9:18 PM EDT
Withdrawn Not applicable Interventional

Diagnosis and Treatment of CAD in Severe PAD After Lower Extremity Revascularization

NCT06387355
View directory record Official record
Conditions
Peripheral Artery Disease, Coronary Artery Disease
Interventions
Coronary computed topography (CT) angiography with FFR-CT
Diagnostic Test
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 1, 2026, 9:18 PM EDT
Completed No phase listed Observational

A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population

NCT06052319
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD)
Interventions
Care4Today® Connect CAD-PAD Mobile Application
Device
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Jacksonville, Florida • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 2 Interventional

Self-Managed Walking Improves Function

NCT00611988
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetes Mellitus
Interventions
Self-managed walking, Control group
Behavioral · Other
Lead sponsor
University of Kansas
Other
Eligibility
40 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 1, 2026, 9:18 PM EDT
Not listed Phase 2 Interventional

Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease

NCT00053716
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Liprostin [liposomal Prostaglandin E1]
Drug
Lead sponsor
Endovasc
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2007 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 1Phase 2 Interventional

Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery

NCT01403337
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ischemic preconditioning, Control
Other
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

NCT01319812
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease
Interventions
Astron Stents, Pulsar Stents
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
Fremont, California • New Haven, Connecticut • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

NCT06167265
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol Tablet 100 mg, PMR Tablet 145 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 4 Interventional Results available

The Jetstream (JET) Post-market Registry

NCT01436435
View directory record Official record
Conditions
Peripheral Arterial Diseases
Interventions
Jetstream Atherectomy System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Miami, Florida • Davenport, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Not applicable Interventional

Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)

NCT00498069
View directory record Official record
Conditions
Ischemia
Interventions
Harvest Smartprep2 BMAC System, SmartPReP2 BMAC System, placebo
Device · Biological
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 1, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

NCT01499134
View directory record Official record
Conditions
Peripheral Artery Disease, Hypertension
Interventions
nebivolol, Metoprolol succinate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 1, 2026, 9:18 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

NCT00424866
View directory record Official record
Conditions
Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Interventions
FGF-1, Placebo
Drug
Lead sponsor
Venturis Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 1, 2026, 9:18 PM EDT